Genfit Stock (NASDAQ:GNFT)
Previous Close
$3.88
52W Range
$3.35 - $6.42
50D Avg
$3.90
200D Avg
$4.37
Market Cap
$186.00M
Avg Vol (3M)
$7.65K
Beta
1.12
Div Yield
-
GNFT Company Profile
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
GNFT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HCWB | HCW Biologics Inc. |
| MOLN | Molecular Partners AG |
| MNOV | MediciNova, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| KROS | Keros Therapeutics, Inc. |
| RZLT | Rezolute, Inc. |
| CSBR | Champions Oncology, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| EWTX | Edgewise Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| FENC | Fennec Pharmaceuticals Inc. |
| JANX | Janux Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| HRMY | Harmony Biosciences Holdings, Inc. |